 |
|
|
| |
Reducing CV risk in patients with MASH independent of baseline statin use: Lp(a) and LDL-C lowering by resmetirom
|
| |
| |
EASL 2026 May 26-30 Barcelona
Meena Bansal,1 Rebecca Taub,2 Dominic Labriola,2 David Soergel,2 Yestle Kim,2 Naim Alkhouri,3 Mazen Noureddin,4 Seth Baum,5 Rohit Loomba6
1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Madrigal Pharmaceuticals, Inc., West Conshohocken, PA, USA; 3Summit Clinical Research, San Antonio, TX, USA; 4Pinnacle Clinical Research, San Antonio, TX, USA; 5Florida Atlantic University, Boca Raton, FL, USA; 6UC San Diego School of Medicine, San Diego, CA, USA
|
| |
|
|
|
|
|
